Our rapid CoVID-19 saliva-based test using an off-the-shelf glucometer was recently funded by the National Institutes of Health (NIH) under the Rapid Acceleration of Diagnostics (RADx) program. Read more about our exciting work here.
NIH R21 funded and featured in the news
The National Institutes of Health (NIH) funded our research on using magnetic sensors to non-invasively monitor both protein and microRNA biomarkers to detect complications in pregnancy. Read more about it here.
NIH Grant for Opioid Sensor
The BioEE group along with Qualcomm Institute’s CARI Therapeutics were awarded an NIH grant to work on an opioid sensor. Read more about it here.
Qualcomm Fellowship
Xiahan and the BioEE group were awarded a Qualcomm Fellow-Mentor-Advisor (FMA) Fellowship to work on an giant magnetoresistive bionsensor array for high sensitivity, point-of-care detection. Congratulations Xiahan!
Qualcomm Institute seed grant awarded
Our proposal titled “Rapid, Ultralow-Cost Multiplexed Point-of-Care (POC) Testing of Infectious Diseases for Global Health” was awarded as part of the CalIt2 Strategic Research Opportunities (CSRO) program. Read more about it here.
CTRI Galvanizing Engineering in Medicine (GEM) seed grant awarded
The BioEE group and Dr. Doug Conrad were awarded a grant to develop a smartphone-based biosensor to monitor pH and pulmonary exacerbation biomarkers in patients with cystic fibrosis (CF). Read more here.
